Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Taking daily stable statin doses for at least 4 weeks prior to screening visit.~* LDL-C between 100-220 mg/dL for patients taking daily high-intensity statin (for 4 weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping all other lipid-regulating drugs and supplements) at the screening visit; or,~* LDL-C between 115-220 mg/dL for patients taking moderate- or low-intensity statin (for 4 weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping all other lipid-regulating drugs and supplements) at the screening visit.~* Must be willing to discontinue other lipid-regulating therapies during the study~Exclusion Criteria:~* History of acute significant cardiovascular disease.~* Current clinically significant cardiovascular disease.~* History of inability to tolerate any statin at any dose due to muscle-related pain or weakness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 + Atorvastatin (Type: EXPERIMENTAL): ETC-1002 180 mg treatment, oral once daily added-on to Atorvastatin 80 mg once daily
- Placebo + Atorvastatin (Type: PLACEBO_COMPARATOR): Placebo treatment, oral once daily added-on to Atorvastatin 80 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).